{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T01:24:11Z","timestamp":1773278651954,"version":"3.50.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2002,3,1]],"date-time":"2002-03-01T00:00:00Z","timestamp":1014940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2002,3,1]],"date-time":"2002-03-01T00:00:00Z","timestamp":1014940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2002,3]]},"DOI":"10.1124\/jpet.300.3.1075","type":"journal-article","created":{"date-parts":[[2003,1,10]],"date-time":"2003-01-10T18:32:29Z","timestamp":1042223549000},"page":"1075-1084","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Methotrexate Exacerbates Tumor Progression in a Murine Model of Chronic Myeloid Leukemia"],"prefix":"10.1016","volume":"300","author":[{"given":"Colin L.","family":"Sweeney","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miechaleen D.","family":"Diers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel L.","family":"Frandsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Gunther","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine M.","family":"Verfaillie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. Scott","family":"McIvor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.300.3.1075_bib1","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/2632","article-title":"In vivo selection of retrovirally transduced hematopoietic stem cells.","volume":"4","author":"Allay","year":"1998","journal-title":"Nat Med"},{"key":"10.1124\/jpet.300.3.1075_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1054-3589(08)60468-8","article-title":"Therapeutic strategies involving the multidrug resistance phenotype: the MDR1 gene as target, chemoprotectant, and selectable marker in gene therapy.","volume":"46","author":"Aran","year":"1999","journal-title":"Adv Pharmacol"},{"key":"10.1124\/jpet.300.3.1075_bib3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1200\/JCO.1993.11.1.5","article-title":"Karnofsky memorial lecture. Ode to methotrexate.","volume":"11","author":"Bertino","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1124\/jpet.300.3.1075_bib4","first-page":"149","article-title":"Use of a temperature-sensitive mutant to define the biological effects of the p210BCR-ABL tyrosine kinase on proliferation of a factor-dependent murine myeloid cell line.","volume":"9","author":"Carlesso","year":"1994","journal-title":"Oncogene"},{"key":"10.1124\/jpet.300.3.1075_bib5","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1182\/blood.V75.2.337.337","article-title":"Serial transplantation of methotrexate-resistant bone marrow: protection of murine recipients from drug toxicity by progeny of transduced stem cells.","volume":"75","author":"Corey","year":"1990","journal-title":"Blood"},{"key":"10.1124\/jpet.300.3.1075_bib6","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","article-title":"Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome.","volume":"247","author":"Daley","year":"1990","journal-title":"Science (Wash DC)"},{"key":"10.1124\/jpet.300.3.1075_bib7","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1182\/blood.V83.10.3068.3068","article-title":"Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML.","volume":"83","author":"Deisseroth","year":"1994","journal-title":"Blood"},{"key":"10.1124\/jpet.300.3.1075_bib8","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.300.3.1075_bib9","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.300.3.1075_bib10","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"key":"10.1124\/jpet.300.3.1075_bib11","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1073\/pnas.80.10.2931","article-title":"Demonstration of permanent factor-dependent multipotential (erythroid\/neutrophil\/basophil) hematopoietic progenitor cell lines.","volume":"80","author":"Greenberger","year":"1983","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.300.3.1075_bib12","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s002770000167","article-title":"Current trends in the management of chronic myelogenous leukemia.","volume":"79","author":"Hehlmann","year":"2000","journal-title":"Ann Hematol"},{"key":"10.1124\/jpet.300.3.1075_bib13","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1182\/blood.V95.1.62","volume":"95","author":"Hochhaus","year":"2000","journal-title":"Blood"},{"key":"10.1124\/jpet.300.3.1075_bib14","first-page":"1286","article-title":"Transgenic mice expressing the tyr22 variant of murine DHFR: protection of transgenic marrow transplant recipients from lethal doses of methotrexate.","volume":"25","author":"James","year":"1997","journal-title":"Exp Hematol"},{"key":"10.1124\/jpet.300.3.1075_bib15","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1182\/blood.V96.4.1334","article-title":"Mild preconditioning and low-level engraftment confer methotrexate resistance in mice transplanted with marrow expressing drug-resistant dihydrofolate reductase activity.","volume":"96","author":"James","year":"2000","journal-title":"Blood"},{"key":"10.1124\/jpet.300.3.1075_bib16","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1056\/NEJM198311033091805","article-title":"The pharmacology and clinical use of methotrexate.","volume":"309","author":"Jolivet","year":"1983","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.300.3.1075_bib17","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3109\/10428199909093742","article-title":"Long-term third chronic phase of chronic myelogenous leukemia maintained by interferon-alpha and methotrexate.","volume":"33","author":"Kanda","year":"1999","journal-title":"Leuk Lymphoma"},{"key":"10.1124\/jpet.300.3.1075_bib18","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations.","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1124\/jpet.300.3.1075_bib19","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood.V83.11.3403.3403","article-title":"Development of a retroviral construct containing a human mutated dihydrofolate reductase cDNA for hematopoietic stem cell transduction.","volume":"83","author":"Li","year":"1994","journal-title":"Blood"},{"key":"10.1124\/jpet.300.3.1075_bib20","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1200\/JCO.1987.5.12.2032","article-title":"Trimetrexate: a second generation folate antagonist in clinical trial.","volume":"5","author":"Lin","year":"1987","journal-title":"J Clin Oncol"},{"key":"10.1124\/jpet.300.3.1075_bib21","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1182\/blood.V86.6.2439.bloodjournal8662439","article-title":"Protection of mice from lethal doses of methotrexate by transplantation with transgenic marrow expressing drug-resistant dihydrofolate reductase activity.","volume":"86","author":"May","year":"1995","journal-title":"Blood"},{"key":"10.1124\/jpet.300.3.1075_bib22","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/S0022-3565(25)20799-6","article-title":"Methotrexate dose-escalation studies in transgenic mice and marrow transplant recipients expressing drug-resistant dihydrofolate reductase activity.","volume":"278","author":"May","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.300.3.1075_bib23","series-title":"Gene Therapy of Cancer","article-title":"Protection from antifolate toxicity by expression of drug-resistant dihydrofolate reductase","author":"McIvor","year":"2002"},{"key":"10.1124\/jpet.300.3.1075_bib24","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/79526","article-title":"Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia.","volume":"6","author":"Molldrem","year":"2000","journal-title":"Nat Med"},{"key":"10.1124\/jpet.300.3.1075_bib25","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/0006-2952(94)90393-X","article-title":"Saturation mutagenesis at dihydrofolate reductase codons 22 and 31. A variety of amino acid substitutions conferring methotrexate resistance.","volume":"47","author":"Morris","year":"1994","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/jpet.300.3.1075_bib26","doi-asserted-by":"crossref","first-page":"162","DOI":"10.2144\/97221rr03","article-title":"Tracking and quantitation of retroviral-mediated transfer using a completely humanized, red-shifted green fluorescent protein gene.","volume":"22","author":"Muldoon","year":"1997","journal-title":"Biotechniques"},{"key":"10.1124\/jpet.300.3.1075_bib27","first-page":"2493","article-title":"Potentiation of methotrexate toxicity by dipyridamole.","volume":"44","author":"Nelson","year":"1984","journal-title":"Cancer Res"},{"key":"10.1124\/jpet.300.3.1075_bib28","first-page":"1245","article-title":"Retroviral-mediated transfer of the murine interleukin-3 gene engineered for intracellular retention results in a myeloproliferative syndrome but is associated with circulating interleukin-3 levels.","volume":"21","author":"Orchard","year":"1993","journal-title":"Exp Hematol"},{"key":"10.1124\/jpet.300.3.1075_bib29","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2307\/2344317","article-title":"Asymptotically efficient rank invariant procedures.","volume":"135","author":"Peto","year":"1972","journal-title":"J R Stat Soc [Ser A]"},{"key":"10.1124\/jpet.300.3.1075_bib30","doi-asserted-by":"crossref","first-page":"14088","DOI":"10.1073\/pnas.93.24.14088","article-title":"Retroviral transduction of a mutant methylguanine DNA methyltransferase gene into human CD34 cells confers resistance to O6-benzylguanine plus 1,3-bis(2-chloroethyl)-1-nitrosourea.","volume":"93","author":"Reese","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.300.3.1075_bib31","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1002\/1097-0142(19900515)65:10<2178::AID-CNCR2820651004>3.0.CO;2-#","article-title":"The Philadelphia chromosome translocation. A paradigm for understanding leukemia.","volume":"65","author":"Rowley","year":"1990","journal-title":"Cancer"},{"key":"10.1124\/jpet.300.3.1075_bib32","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1073\/pnas.80.9.2495","article-title":"Isolation and expression of an altered mouse dihydrofolate reductase cDNA.","volume":"80","author":"Simonsen","year":"1983","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.300.3.1075_bib33","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1089\/15258160050079425","article-title":"Drug therapy for acute graft-versus-host disease prophylaxis.","volume":"9","author":"Simpson","year":"2000","journal-title":"J Hematother Stem Cell Res"},{"key":"10.1124\/jpet.300.3.1075_bib34","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1182\/blood.V87.6.2579.bloodjournal8762579","article-title":"A gene transfer strategy for making bone marrow cells resistant to trimetrexate.","volume":"87","author":"Spencer","year":"1996","journal-title":"Blood"},{"key":"10.1124\/jpet.300.3.1075_bib35","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1177\/030089169307900613","article-title":"Reversal of methotrexate-induced folate pool depletion by thymidine in a human leukemia cell line in vitro.","volume":"79","author":"Sur","year":"1993","journal-title":"Tumori"},{"key":"10.1124\/jpet.300.3.1075_bib36","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1634\/theoncologist.1-1-68","article-title":"New antifolates: pharmacology and clinical applications.","volume":"1","author":"Takimoto","year":"1996","journal-title":"Oncologist"},{"key":"10.1124\/jpet.300.3.1075_bib37","doi-asserted-by":"crossref","first-page":"4603","DOI":"10.1182\/blood.V86.12.4603.bloodjournal86124603","article-title":"BCR\/ABL P210 and P190 cause distinct leukemia in transgenic mice.","volume":"86","author":"Voncken","year":"1995","journal-title":"Blood"},{"key":"10.1124\/jpet.300.3.1075_bib38","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0006-2952(99)00311-1","article-title":"Maintenance of differential methotrexate toxicity between cells expressing drug-resistant and wild-type dihydrofolate reductase activities in the presence of nucleosides through nucleoside transport inhibition.","volume":"59","author":"Warlick","year":"2000","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/jpet.300.3.1075_bib39","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1097\/00007890-199106000-00010","article-title":"Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation.","volume":"51","author":"Weisdorf","year":"1991","journal-title":"Transplantation"},{"key":"10.1124\/jpet.300.3.1075_bib40","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1084\/jem.166.1.210","article-title":"Protection of bone marrow transplant recipients from lethal doses of methotrexate by the generation of methotrexate-resistant bone marrow.","volume":"166","author":"Williams","year":"1987","journal-title":"J Exp Med"},{"key":"10.1124\/jpet.300.3.1075_bib41","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1172\/JCI10196","article-title":"Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia.","volume":"106","author":"Wu","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1124\/jpet.300.3.1075_bib42","doi-asserted-by":"crossref","first-page":"4687","DOI":"10.1182\/blood.V90.12.4687","article-title":"Gene therapy for chronic myelogenous leukemia (CML): a retroviral vector that renders hematopoietic progenitors methotrexate-resistant and CML progenitors functionally normal and nontumorigenic in vivo.","volume":"90","author":"Zhao","year":"1997","journal-title":"Blood"},{"key":"10.1124\/jpet.300.3.1075_bib43","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1089\/hum.1997.8.8-903","article-title":"Post-transplant methotrexate administration leads to improved curability of mice bearing a mammary tumor transplanted with marrow transduced with a mutant human dihydrofolate reductase cDNA.","volume":"8","author":"Zhao","year":"1997","journal-title":"Hum Gene Ther"},{"key":"10.1124\/jpet.300.3.1075_bib44","first-page":"27","article-title":"Long-term protection of recipient mice from lethal doses of methotrexate by marrow infected with a double-copy vector retrovirus containing a mutant dihydrofolate reductase.","volume":"1","author":"Zhao","year":"1994","journal-title":"Cancer Gene Ther"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524355570?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524355570?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.300.3.1075","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T23:16:13Z","timestamp":1740006973000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524355570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,3]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2002,3]]}},"alternative-id":["S0022356524355570"],"URL":"https:\/\/doi.org\/10.1124\/jpet.300.3.1075","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2002,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Methotrexate Exacerbates Tumor Progression in a Murine Model of Chronic Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.300.3.1075","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2002 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}